Table 3.
Jakinibs and Statinibs
| Drug | Target | Status | Diseases |
|---|---|---|---|
| Ruxolitinib (INC424) | JAK1, JAK2 |
FDA approved Phase II Phase 2b |
Polycythemia, Myelofibrosis, Various cancers Psoriasis (topical) |
| Tofacitinib | JAK3>JAK1≫ (JAK2) |
FDA approved Phase III Phase II |
RA Psoriasis, Ulcerative colitis spondyloarthropathy, JIA Transplant rejection |
| Oclacitinib | JAK1 | FDA approved | Canine allergic dermatitis |
| ABT494 | JAK1 | Phase II | RA, Crohn’s |
| Baricitinib | JAK1, JAK2 | Phase II | RA, Psoriasis, Diabetic nephropathy, autoinflammatory disease |
| Momelitinib | JAK1, JAK2 | Phase III | Myelofibrosis |
| GLPG0634(filgotinib) | JAK1 | Phase II | RA, Crohn’s |
| INCB047986 | JAK inhibitor | Phase I | Lymphoma, solid tumors |
| INCB039110 | JAK1, JAK2 | Phase II | Psoriasis, RA |
| CYT387 | JAK1, JAK2 | Phase II | Myelofibrosis |
| ASP015K | JAK 3/JAK1≫ JAK2/TYK2 |
Phase II | Psoriasis, RA |
| R333 | JAK/SYK | Phase II | Discoid lupus (topical) |
| PF-04965842 | JAK1 | Phase I | healthy adults |
| GLG0778 | JAK1 | Phase II | SLE |
| GSK2586184 | JAK1 | Phase II | SLE, Psoriasis |
| VX-509 (decernotinib) | JAK3 | Phase IIb | RA |
| Lestaurtinib | FLT3, JAK2, TRKs | Phase II | AML, PCV/ET, myelofibrosis |
| Pacritinib | JAK2 | Phase II | Myelofibrosis, myeloid leukemias, MDS |
| LY2784544 | JAK2 | Phase II Phase I |
myelofibrosis various cancers |
| AZD1480 | JAK1, JAK2 | Phase I | myeloproliferative diseases, various cancers |
| XL019 | JAK2 | Phase I, terminated | Myelofibrosis, PCV |
| BMS-911543 | JAK2 | Phase II | Myelofibrosis |
| NS-108 | JAK2, SRC | Phase II | Myelofibrosis |
| PF-06263276 | pan-JAK | Phase I | healthy (topical) |
| SV1578 | JAK2, Flt3 | Phase I | healthy adults |
| ISIS-STAT3Rx (AZD9150) | STAT3 | Phase II | various cancers |
| OPB-51602 | STAT3 | Phase I | nasopharyngeal carcinoma |
| OPB-31121 | STAT3 | Phase I | various cancers |